{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-131965","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.464343+00:00","generated_at":"2026-05-29T11:27:35.182928+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Olema Pharma enters Novartis collaboration for Phase 3 breast cancer trial and raises $250M","bullets":["Collaboration with Novartis provides ribociclib supply for planned Phase 3 OPERA-02 trial of palazestrant in ER+/HER2- frontline advanced/metastatic breast cancer, initiation expected mid-2025.","$250M private placement: 19,928,875 shares at $9.08 and pre-funded warrants for 7,604,163 shares; gross proceeds ~$250M, closing expected Dec 4, 2024.","Novartis receives right of first negotiation on any sale of palazestrant or change of control; repayment obligation of up to ~$275M proportional to ribociclib supplied.","Proceeds to fund OPERA-02, Phase 1/2 OP-3136 study, ongoing Phase 3 OPERA-01 monotherapy trial; OPERA-01 topline data expected in 2026.","Investors include Adage Capital, Bain Capital Life Sciences, BVF, Driehaus, Janus Henderson, Paradigm, Wellington, Woodline, and a large investment manager."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-131965","json":"https://secwatch.observer/filing/0000950170-24-131965.json","markdown":"https://secwatch.observer/filing/0000950170-24-131965.md","text":"https://secwatch.observer/filing/0000950170-24-131965.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024131965/0000950170-24-131965-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024131965/olma-20241129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T11:27:35.182928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}